1
|
Sia D, Villanueva A, Friedman SL and
Llovet JM: Liver cancer cell of origin, molecular class, and
effects on patient prognosis. Gastroenterology. 152:745–761.
2017.PubMed/NCBI View Article : Google Scholar
|
2
|
Ikeda K: Recent advances in medical
management of hepatocellular carcinoma. Hepatol Res. 49:14–32.
2019.PubMed/NCBI View Article : Google Scholar
|
3
|
Kawaoka T, Aikata H, Kobayashi T, Uchikawa
S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, et al:
Comparison of hepatic arterial infusion chemotherapy between
5-fluorouracil-based continuous infusion chemotherapy and low-dose
cisplatin monotherapy for advanced hepatocellular carcinoma.
Hepatol Res. 48:1118–1130. 2018.PubMed/NCBI View Article : Google Scholar
|
4
|
Shang X, Li G, Liu H, Li T, Liu J, Zhao Q
and Wang C: Comprehensive circular RNA profiling reveals that
hsa_circ_0005075, a new circular RNA biomarker, is involved in
hepatocellular carcinoma development. Medicine (Baltimore).
95(e3811)2016.PubMed/NCBI View Article : Google Scholar
|
5
|
Sun X and Malhotra A: Noncoding RNAs
(ncRNA) in hepato cancer: A review. J Environ Pathol Toxicol Oncol.
37:15–25. 2018.PubMed/NCBI View Article : Google Scholar
|
6
|
Lanzafame M, Bianco G, Terracciano LM, Ng
C and Piscuoglio S: The role of long non-coding RNAs in
hepatocarcinogenesis. Int J Mol Sci. 19(E682)2018.PubMed/NCBI View Article : Google Scholar
|
7
|
Qiu LP, Wu YH, Yu XF, Tang Q, Chen L and
Chen KP: The emerging role of circular RNAs in hepatocellular
carcinoma. J Cancer. 9:1548–1559. 2018.PubMed/NCBI View Article : Google Scholar
|
8
|
Liu BH, Zhang BB, Liu XQ, Zheng S, Dong KR
and Dong R: Expression profiling identifies circular RNA signature
in hepatoblastoma. Cell Physiol Biochem. 45:706–719.
2018.PubMed/NCBI View Article : Google Scholar
|
9
|
Wang M, Yang Y, Xu J, Bai W, Ren X and Wu
H: CircRNAs as biomarkers of cancer: A meta-analysis. BMC Cancer.
18(303)2018.PubMed/NCBI View Article : Google Scholar
|
10
|
Zhu Q, Lu G, Luo Z, Gui F, Wu J, Zhang D
and Ni Y: CircRNA circ_0067934 promotes tumor growth and metastasis
in hepatocellular carcinoma through regulation of
miR-1324/FZD5/Wnt/β-catenin axis. Biochem Biophys Res Commun.
497:626–632. 2018.PubMed/NCBI View Article : Google Scholar
|
11
|
Shi L, Yan P, Liang Y, Sun Y, Shen J, Zhou
S, Lin H, Liang X and Cai X: Circular RNA expression is suppressed
by androgen receptor (AR)-regulated adenosine deaminase that acts
on RNA (ADAR1) in human hepatocellular carcinoma. Cell Death Dis.
8(e3171)2017.PubMed/NCBI View Article : Google Scholar
|
12
|
Zhang X, Qiu S, Luo P, Zhou H, Jing W,
Liang C and Tu J: Down-regulation of hsa_circ_0001649 in
hepatocellular carcinoma predicts a poor prognosis. Cancer Biomark.
22:135–142. 2018.PubMed/NCBI View Article : Google Scholar
|
13
|
Han D, Li J, Wang H, Su X, Hou J, Gu Y,
Qian C, Lin Y, Liu X, Huang M, et al: Circular RNA circMTO1 acts as
the sponge of microRNA-9 to suppress hepatocellular carcinoma
progression. Hepatology. 66:1151–1164. 2017.PubMed/NCBI View Article : Google Scholar
|
14
|
Shao YY, Liang PC, Wu YM, Huang CC, Huang
KW, Cheng JC, Hsu CH, Hsu C, Cheng AL and Lin ZZ: A pilot study of
hepatic arterial infusion of chemotherapy for patients with
advanced hepatocellular carcinoma who have failed anti-angiogenic
therapy. Liver Int. 33:1413–1419. 2013.PubMed/NCBI View Article : Google Scholar
|
15
|
Wakamatsu T, Nakahashi Y, Hachimine D,
Seki T and Okazaki K: The combination of glycyrrhizin and
lamivudine can reverse the cisplatin resistance in hepatocellular
carcinoma cells through inhibition of multidrug
resistance-associated proteins. Int J Oncol. 31:1465–1472.
2007.PubMed/NCBI
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
17
|
Fu J and Wang H: Precision diagnosis and
treatment of liver cancer in China. Cancer Lett. 412:283–288.
2018.PubMed/NCBI View Article : Google Scholar
|
18
|
Tsuchiya N, Sawada Y, Endo I, Saito K,
Uemura Y and Nakatsura T: Biomarkers for the early diagnosis of
hepatocellular carcinoma. World J Gastroenterol. 21:10573–10583.
2015.PubMed/NCBI View Article : Google Scholar
|
19
|
Amable L: Cisplatin resistance and
opportunities for precision medicine. Pharmacol Res. 106:27–36.
2016.PubMed/NCBI View Article : Google Scholar
|
20
|
Hu Y, Zhu QN, Deng JL, Li ZX, Wang G and
Zhu YS: Emerging role of long non-coding RNAs in cisplatin
resistance. Onco Targets Ther. 11:3185–3194. 2018.PubMed/NCBI View Article : Google Scholar
|
21
|
Kataoka J, Shiraha H, Horiguchi S,
Sawahara H, Uchida D, Nagahara T, Iwamuro M, Morimoto H, Takeuchi
Y, Kuwaki K, et al: Loss of Runt-related transcription factor 3
induces resistance to 5-fluorouracil and cisplatin in
hepatocellular carcinoma. Oncol Rep. 35:2576–2582. 2016.PubMed/NCBI View Article : Google Scholar
|
22
|
Kim Y, Jang M, Lim S, Won H, Yoon KS, Park
JH, Kim HJ, Kim BH, Park WS, Ha J and Kim SS: Role of cyclophilin B
in tumorigenesis and cisplatin resistance in hepatocellular
carcinoma in humans. Hepatology. 54:1661–1678. 2011.PubMed/NCBI View Article : Google Scholar
|
23
|
Achkar IW, Abdulrahman N, Al-Sulaiti H,
Joseph JM, Uddin S and Mraiche F: Cisplatin based therapy: The role
of the mitogen activated protein kinase signaling pathway. J Transl
Med. 16(96)2018.PubMed/NCBI View Article : Google Scholar
|
24
|
Xu N, Chen S, Liu Y, Li W, Liu Z, Bian X,
Ling C and Jiang M: Profiles and bioinformatics analysis of
differentially expressed Circrnas in taxol-resistant non-small cell
lung cancer cells. Cell Physiol Biochem. 48:2046–2060.
2018.PubMed/NCBI View Article : Google Scholar
|
25
|
Ding B, Lou W, Xu L and Fan W: Non-coding
RNA in drug resistance of hepatocellular carcinoma. Biosci Rep.
38(BSR20180915)2018.PubMed/NCBI View Article : Google Scholar
|
26
|
Shao F, Huang M, Meng F and Huang Q:
Circular RNA signature predicts gemcitabine resistance of
pancreatic ductal adenocarcinoma. Front Pharmacol.
9(584)2018.PubMed/NCBI View Article : Google Scholar
|
27
|
Kun-Peng Z, Xiao-Long M, Lei Z, Chun-Lin
Z, Jian-Ping H and Tai-Cheng Z: Screening circular RNA related to
chemotherapeutic resistance in osteosarcoma by RNA sequencing.
Epigenomics. 10:1327–1346. 2018.PubMed/NCBI View Article : Google Scholar
|
28
|
Liu Y, Dong Y, Zhao L, Su L and Luo J:
Circular RNAMTO1 suppresses breast cancer cell viability and
reverses monastrol resistance through regulating the TRAF4/Eg5
axis. Int J Oncol. 53:1752–1762. 2018.PubMed/NCBI View Article : Google Scholar
|
29
|
Kun-Peng Z, Xiao-Long M and Chun-Lin Z:
Overexpressed circPVT1, a potential new circular RNA biomarker,
contributes to doxorubicin and cisplatin resistance of osteosarcoma
cells by regulating ABCB1. Int J Biol Sci. 14:321–330.
2018.PubMed/NCBI View Article : Google Scholar
|